Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinicnews2022-01-20T13:18:44+00:00January 20th, 2022|FierceBiotech|
Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcountnews2022-01-20T10:27:33+00:00January 20th, 2022|FierceBiotech|
Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen’s Aduhelmnews2022-01-19T18:56:13+00:00January 19th, 2022|FierceBiotech|
Fierce JPM Week: As Novartis tries to avoid ‘me-too’ meds in M&A hunt, R&D chief urges biotechs to ‘please reach out’news2022-01-19T17:59:44+00:00January 19th, 2022|FierceBiotech|
Charles River diving deeper into AI drug development in partnership with Valo Healthnews2022-01-19T15:09:25+00:00January 19th, 2022|FierceBiotech|
Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse diseasenews2022-01-19T11:36:27+00:00January 19th, 2022|FierceBiotech|
Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he begannews2022-01-19T10:42:58+00:00January 19th, 2022|FierceBiotech|
Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDAnews2022-01-18T14:07:20+00:00January 18th, 2022|FierceBiotech|
With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapynews2022-01-18T13:26:53+00:00January 18th, 2022|FierceBiotech|
Fierce JPM Week: Johnson & Johnson’s JLABS—Taming the beast, while letting it roam the worldnews2022-01-18T12:38:25+00:00January 18th, 2022|FierceBiotech|
